Tarsus Pharmaceuticals (TARS) reported $451M in revenue for fiscal 2025, +146.7% year on year. That ranks #2277 by revenue among 2853 SEC filers and #223 in Healthcare. It posted a net loss of −$66.0M for the same year. The fiscal 2025 balance sheet shows $562M in total assets, $184M in cash and $72.4M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $451M | +146.7% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$71.0M | +$49.6M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$66.0M | +$50.0M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$12.5M | +$70.6M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $9.9M | +529.2% | FY20252025-12-31 |
| Total assetsAssets | $562M | +49.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $343M | +53.0% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $184M | +93.7% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $72.4M | +0.8% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $162M | −$7.0M | Open → |
| Q2 20262026-06-30 | $174M | −$18.6M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Tarsus Pharmaceuticals, Inc.
- Ticker
- TARS
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0001819790
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 23, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Natures Sunshine ProductsNATR | $480M | $19.5M |
| Zai LabZLAB | $460M | −$176M |
| AccurayARAY | $459M | −$1.6M |
| Tarsus PharmaceuticalsTARS | $451M | −$66.0M |
| ArtivionAORT | $441M | $9.8M |
| Genedx HoldingsWGS | $428M | −$21.0M |
| Mimedx GroupMDXG | $419M | $48.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Tarsus Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/tarsus-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Tarsus Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/tarsus-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-tarsus-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Tarsus Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/tarsus-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001819790-26-000019 · February 23, 2026
{{cite web |title=Tarsus Pharmaceuticals — Key figures — 10-K (0001819790-26-000019) |url=https://www.sec.gov/Archives/edgar/data/1819790/000181979026000019/tars-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-23}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.